



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 4.11.2022

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai — 400070

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 4th November, 2022 -Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e. Friday, 4th November, 2022 had inter-alia transacted and approved the following items of business:

- 1, Approved the Un-audited Financial Results long with the Segment results for the quarter and half year ended 30th September, 2022.
2. Approved the Statement of Assets and Liabilities as at 30th September, 2022.
3. Approved the Cash Flow Statement as at 30th September, 2022.

We herewith enclose the following:

- A. Un-Audited financial Results, Segment Results, the Statement of Assets and Liabilities and Cash Flow statement as at 30th September, 2022.
- B. Limited Review Report of the Statutory Auditors for the quarter and half year ended 30th September, 2022.

Kindly take the above on your records.

Thanking you

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 11:10 PM

SIGACHI LABORATORIES LIMITED

CIN:L24230TG1994PLC018786

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

Statement of Un-audited Financial Results For The Quarter and Half Year Ended 30th September, 2022

(Rs. In Lakhs)

| Sl.No | Particulars | Quarter ended | | | Half - Year ended | | Year ended |
|-------|--|---------------|--------------|--------------|-------------------|--------------|------------|
| | | 30.09.2022 | 30.06.2022 | 30.09.2021 | 30.09.2022 | 30.09.2021 | 31.03.2022 |
| | | (Un-audited) | (Un-audited) | (Un-audited) | (Un-audited) | (Un-audited) | (Audited) |
| 1 | Revenue from operations | 64.26 | 37.21 | 100.87 | 101.47 | 176.13 | 259.68 |
| 2 | Other income | 13.99 | 6.97 | 6.77 | 20.96 | 15.26 | 44.10 |
| 3 | Total Income (1+2) | 78.25 | 44.18 | 107.64 | 122.43 | 191.39 | 303.78 |
| 4 | Expenses | | | | | | |
| | a) Cost of materials consumed | - | - | - | - | - | - |
| | b) Purchase of Stock-in-Trade | - | - | - | - | - | - |
| | c) Fair value loss | (39.59) | 39.59 | - | - | - | - |
| | d) Employee benefits expense | 9.31 | 8.39 | 9.52 | 17.70 | 16.04 | 34.16 |
| | e) Finance costs | - | - | - | - | - | - |
| | f) Depreciation and amortization expense | 4.61 | 4.23 | 4.17 | 8.84 | 8.35 | 16.82 |
| | g) Other expenses | 3.73 | 3.84 | 3.38 | 7.57 | 7.03 | 15.41 |
| | Total Expenses | (21.94) | 56.05 | 17.07 | 34.11 | 31.42 | 66.39 |
| 5 | Profit/(Loss) before exceptional items and tax (3-4) | 100.19 | (11.87) | 90.57 | 88.32 | 159.97 | 237.39 |
| 6 | Exceptional Items | - | - | - | - | - | - |
| 7 | Profit/(Loss) before tax (5-6) | 100.19 | (11.87) | 90.57 | 88.32 | 159.97 | 237.39 |
| 8 | Tax expense | | | | | | |
| | (a) Current tax | 10.48 | 8.43 | 8.74 | 18.91 | 15.17 | 39.66 |
| | (b) Deferred tax | 10.44 | (14.68) | (0.13) | (4.24) | (0.27) | (1.91) |
| | Total Tax Expense | 20.92 | (6.25) | 8.61 | 14.67 | 14.90 | 37.75 |
| 9 | Profit/(Loss) for the Period (7-8) | 79.27 | (5.62) | 81.96 | 73.65 | 145.07 | 199.64 |
| 10 | Other Comprehensive income (OCI) | | | | | | |
| | (a) Items that will not be reclassified to profit or loss | 60.50 | (112.99) | 74.88 | (52.49) | 169.62 | 98.03 |
| | (b) Remeasurement gains / (losses) on defined benefit plans | - | - | - | - | - | (0.16) |
| | Tax on Items that will not be reclassified to profit or loss | - | - | - | - | - | 0.04 |
| | (c) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | Total Other Comprehensive income | 60.50 | (112.99) | 74.88 | (52.49) | 169.62 | 97.91 |
| | Total Comprehensive income (9+10) | 139.77 | (118.61) | 156.84 | 21.16 | 314.69 | 297.55 |
| 11 | Paid-up Equity Share Capital (Face Value Rs.10/- per share) | 675.31 | 675.31 | 675.31 | 675.31 | 675.31 | 675.31 |
| 12 | Other Equity | - | - | - | - | - | 2,243.74 |
| 13 | Earnings per equity share (of Rs.10/- each) (not annualized (Rs.)) | | | | | | |
| | (1) Basic | 1.17 | (0.08) | 1.21 | 1.09 | 2.15 | 2.96 |
| | (2) Diluted | 1.17 | (0.08) | 1.21 | 1.09 | 2.15 | 2.96 |

Segment wise Revenue, Results and Capital Employed for the Quarter and Half Year Ended 30th September, 2022

(Rs.in Lakhs)

| Sl.No | Particulars | Quarter ended | | | Half - year ended | | Year ended |
|-------|--|---------------|--------------|--------------|-------------------|--------------|------------|
| | | 30.09.2022 | 30.06.2022 | 30.09.2021 | 30.09.2022 | 30.09.2021 | 31.03.2022 |
| | | (Un-audited) | (Un-audited) | (Un-audited) | (Un-audited) | (Un-audited) | (Audited) |
| 1 | Segment Revenue | | | | | | |
| | a) Bulk Drugs and Intermediates (Lease Rents) | 31.50 | 21.00 | 30.00 | 52.50 | 50.00 | 122.50 |
| | b) Investments | 86.34 | (16.42) | 77.64 | 69.93 | 141.39 | 181.28 |
| | Total | 117.84 | 4.58 | 107.64 | 122.43 | 191.39 | 303.78 |
| | Less: Inter Segment Revenue | | - | - | - | - | - |
| | Net sales/Income from Operations | 117.84 | 4.58 | 107.64 | 122.43 | 191.39 | 303.78 |
| 2 | Segment Results Profit/(Loss) before tax and finance Costs from each segment | | | | | | |
| | a) Bulk Drugs and Intermediates (Lease Rents) | 26.76 | 16.26 | 25.66 | 43.02 | 40.90 | 104.25 |
| | b) Investments | 86.34 | (16.42) | 77.64 | 69.93 | 141.39 | 181.28 |
| | Total | 113.10 | (0.16) | 103.30 | 112.95 | 182.29 | 285.53 |
| | Less: (i) Finance Costs | - | - | - | - | - | - |
| | (ii) Other Un-allocable Expenditure net off | 12.91 | 11.71 | 12.73 | 24.63 | 22.32 | 48.14 |
| | (iii) Un-allocable income | - | - | - | - | - | - |
| | Total Profit Before Tax | 100.19 | (11.87) | 90.57 | 88.32 | 159.97 | 237.39 |
| 3 | Capital Employed | | | | | | |
| | (Segment assets – Segment liabilities) | | | | | | |
| | a) Bulk Drugs and Intermediates | 698.14 | 657.88 | 600.51 | 698.14 | 600.51 | 641.33 |
| | b) Investments | 2,297.82 | 2,198.31 | 2,391.42 | 2,297.82 | 2,391.42 | 2,333.46 |
| | Total | 2,995.96 | 2,856.19 | 2,991.93 | 2,995.96 | 2,991.93 | 2,974.79 |

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 04th November, 2022. These Financial Results are also available on the website of the Metropolitan Stock Exchange of India Limited (www.msei.in) and also on the web site of the company (www.slllab.com).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

By Order of the Board
for Sigachi Laboratories Limited

Place : Hyderabad
Date : 04.11.2022

(T.R.Sekhar)
Executive Director
DIN:02943146

| Sigachi Laboratories Limited | | |
|--|--|---|
| CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September, 2022 | | |
| Particulars | For the Half year Ended 30.09.2022 Rs. | For the year Ended 31.03.2022 Rs. |
| Cash Flows from Operating Activities | | |
| Net profit before tax | 88.32 | 237.39 |
| Adjustments for : | | |
| Depreciation and amortization expenses | 8.84 | 16.82 |
| (Profit)/Loss on sale of Property, Plant and Equipment | - | (0.46) |
| Dividends Received | (15.94) | (33.25) |
| Provision for Gratuity & Leave Encashment | - | 1.43 |
| Profit on sale of mutual funds | (0.33) | - |
| Bad Deposits Recovery | - | (0.16) |
| Bad Debts Recovery | (0.09) | (0.88) |
| Loss due to floods to compoundwall | - | 0.02 |
| Interest | (39.80) | (63.85) |
| Fair Value (Gains)/Losses | (13.77) | (82.68) |
| Operating profit before working capital changes | 27.23 | 74.38 |
| Movements in Working Capital | | |
| (Increase)/Decrease in Trade Receivables | (22.00) | (15.89) |
| (Increase)/Decrease in Other Financial Assets | (23.15) | (52.59) |
| (Increase)/Decrease in Other Current Assets | (3.83) | 111.19 |
| (Increase)/Decrease in Other Non Current Assets | - | (286.01) |
| Increase/(Decrease) in Other Financial Liabilities | 4.99 | (9.21) |
| (Increase)/Decrease in Other Non Current Financial Assets | 0.13 | (0.21) |
| Changes in Working Capital | (43.86) | (252.72) |
| Cash generated from operations | (16.63) | (178.34) |
| Direct Taxes Paid | 16.07 | 37.72 |
| Net Cash from operating activities (A) | (32.70) | (216.06) |
| Cash flows from Investing Activities | | |
| (Purchase) of Property, Plant and Equipment | (26.81) | (1.63) |
| Insurance Claim Received | - | 1.97 |
| (Purchase)/Sale of Investments (Net Agregate) | - | (124.27) |
| Purchase of Investments | (37.11) | - |
| Sale of Investments | 105.75 | - |
| Dividends Received | 15.94 | 33.25 |
| Bad Deposits Recovery | - | 0.16 |
| Bad Debts Recovery | 0.09 | 0.89 |
| Procceds from sale of Property, Plant and Equipment | - | 0.48 |
| Interest Received | 39.80 | 63.85 |
| (Increase)/Decrease in other term deposits | (8.50) | 79.05 |
| Net Cash used in Investing Activities (B) | 89.16 | 53.75 |
| Cash flows from/(used in) Financing Activities | | |
| Proceeds from Long term borrowings | - | - |
| Repayment/(Proceeds) of/from Short-term borrowings | - | - |
| Dividend paid | - | - |
| Net Cash used in Financing Activities (C) | - | - |
| Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C) | 56.46 | (162.31) |
| Cash and Cash Equivalents at the beginning of the year | 80.66 | 242.97 |
| Cash and Cash Equivalents at the ending of the year | 137.12 | 80.66 |

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 04.11.2022

(T.R.Sekhar)
Executive Director
DIN:02943146

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313.

Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website: www.slllab.com, Email: sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Assets and Liabilities as at 30th September, 2022

(Rs. In Lakhs)

| Particulars | As at 30.09.2022 | As at 31.03.2022 |
|--|------------------|------------------|
| | Un-Audited | Audited |
| A. ASSETS | | |
| 1. Non-Current Assets | | |
| (a) Property Plant and Equipment | 246.56 | 228.58 |
| (b) Financial Assets | | |
| (i) Investments | 2,052.91 | 2,111.72 |
| (ii) Other Financial Assets | 43.62 | 43.74 |
| (c) Other non Current Assets | 286.01 | 286.01 |
| Total Non - Current Assets | 2,629.10 | 2,670.05 |
| 2. Current Assets | | |
| (a) Financial Assets | | |
| (i) Investments | - | 39.73 |
| (ii) Trade Receivables | 37.89 | 15.89 |
| (iii) Cash and Cash Equivalents | 137.12 | 80.66 |
| (iv) Other Financial Assets | 244.90 | 221.75 |
| (b) Other Current Assets | 3.83 | - |
| Total Current Assets | 423.74 | 358.03 |
| Total Assets | 3,052.84 | 3,028.08 |
| B. EQUITY AND LIABILITIES | | |
| 1. Equity | | |
| (a) Equity Share Capital | 731.06 | 731.06 |
| (b) Other Equity | 2,264.90 | 2,243.73 |
| Total Equity | 2,995.96 | 2,974.79 |
| 2. Liabilities | | |
| Non-Current Liabilities | | |
| (a) Financial Liabilities | - | - |
| (b) Long term Provisions | 5.88 | 5.88 |
| (c) Deferred Tax Liabilities (net) | 11.49 | 15.72 |
| (d) Other non - Current Liabilities | 25.00 | 25.00 |
| Total Non - Current Liabilities | 42.37 | 46.60 |
| Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | - | - |
| (ii) Trade Payables | - | - |
| (iii) Other Financial Liabilities | 11.67 | 6.69 |
| (b) Provisions | 2.84 | - |
| (c) Other Current Liabilities | - | - |
| Total Current Liabilities | 14.51 | 6.69 |
| Total Equity and Liabilities | 3,052.84 | 3,028.08 |

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 04.11.2022



Independent Auditor's Report on Quarterly and Year to date Unaudited financial Results of M/s Sigachi Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing and Obligations and Disclosure requirements) Regulations, 2015.



To the Board of Directors of,
Sigachi Laboratories Limited.

We have reviewed the accompanying statement of unaudited financial results of **Sigachi Laboratories Limited** ('The Company') for the quarter ended September 30, 2022 and for the period from 1st April, 2022 to 30th September, 2022. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements.

For NSVR & Associates LLP,
Chartered Accountants,
FRN: 008801S/S200060.

N V Gangadhara Rao
Partner,

Membership No: 219486

UDIN: **22219486BCBEBA8765**

Place: Hyderabad

Date: 04/11/2022.